Work stress and metabolic and hemostatic risk factors

Psychosomatic Medicine

Volumn 61, Issue 6, 1999, Pages 796-805

  Vrijkotte, Tanja G M ^a   Van Doornen, Lorenz J P ^b   De Geus, Eco J C ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Chronic stress; Fibrinolysis; Insulin resistance syndrome; Overcommitment

Indexed keywords

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COPING BEHAVIOR; FIBRINOLYSIS; HUMAN; INSULIN RESISTANCE; MENTAL STRESS; OCCUPATIONAL HEALTH; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032755327     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199911000-00012     Document Type: Article

References (71)

1. Lynch J, Krause N, Kaplan GA, Salonen R, Salonen JT. Workplace demands, economic reward, and progression of carotid atherosclerosis. Circulation 1997;96:302-7.
2. Siegrist J, Peter R. Job Stressors and coping characteristics in work-related disease: issues of validity. Work Stress 1994;8: 130-40.
3. Marmot M, Elliot P, editors. Coronary heart disease epidemiology. Oxford, UK: Oxford University Press; 1992.
4. Siegrist J. Adverse health effects of high-effort/low-reward conditions. J Occup Health Psychol 1996;1:27-41.
5. Räikkönen K, Keltikangas-Järvinen L, Hautanen A. The role of psychological coronary risk factors in insulin and glucose metabolism. J Psychosom Res 1998;38:705-13.
6. Niaura R, Stoney CM, Herbert PN. Lipids in psychological research: the last decade. Biol Psychol 1992;34:1-43.
7. Dustan HP. Behavioral factors in hypertension: overview: Circulation 1987;76(suppl 1):57-9.
8. Kaplan JR, Manuck SB, Williams JK, Strawn W. Psychosocial influences on atherosclerosis: evidence for effects and mechanisms in nonhuman primates. In: Blascovich J, Katlin ES, editors. Cardiovascular reactivity to psychological stress and disease. Washington DC: American Psychological Association; 1993. p. 3-26.
9. Saab PG, Schneiderman N. Biobehavioral Stressors, laboratory investigation and the risk of hypertension. In Blascovich J, Katlin ES, editors. Cardiovascular reactivity to psychological stress and disease. Washington DC: American Psychological Association; 1993. p. 49-82.
10. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
11. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia 1991;34:416-22.
12. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993;70:1-38.
13. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993;70:138-43.
14. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
15. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
16. Kluft C. Constitutive synthesis of tissue-type plasminogen activator (tPa) and plasminogen activator inhibitor type 1 (PAI-1): conditions and therapeutic targets. Fibrinolysis 1994;8(Suppl 2):1-7.
17. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
18. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79:129-33.
19. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PTVM, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction: the Rotterdam Study. Circulation 1997;95:2623-7.
20. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
21. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991;34:179-92.
22. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. Arterioscler Thromb 1993;13:1865-73.
23. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997;78: 656-60.
24. Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. Atherosclerosis 1989;80:9-16.
25. Lindahl B, Asplund K, Eliasson M, Evrin PE. Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study. Int J Epidemiol 1996;25:291-9.
26. Toft I, Bønaa KH, Ingebretsen OC, Nordøy A, Birkeland KI, Jenssen T. Gender differences in the relationship between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vase Biol 1997;17:553-9.
27. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympathoadrenal activation of fibrinolysis. Thromb Haemost 1990;63:482-7.
28. Jem C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jem S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989;62:767-71.
29. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med 1991;52:643-68.
30. Schnall PL, Landbergis PA, Baker D. Job strain and cardiovascular disease. Annu Rev Public Health 1994;15:381-411.
31. Wamala SP, Wolk A, Schenk-Gustafsson K, Orth-Gomer K. Lipid profile and socioeconomic status in healthy middle-aged women in Sweden. J Epidemiol Community Health 1997;51: 400-7.
32. Markowe HLJ, Marmot MG, Shipley MJ, Bulpitt CJ, Meade TW, Stirling Y, Vickers MV, Semmence A. Fibrinogen: a possible link between social class and coronary heart disease. BMJ 1985; 291:1312-4.
33. Siegrist J, Peter R, Cremer P, Seidel D. Chronic work stress is associated with atherogenic lipids and elevated fibrinogen in middle-aged men. J Intern Med 1997;242:149-56.
34. Peter R, Alfredsson L, Hammer N, Siegrist J, Theorell T, Westerholm P. High effort, low reward, and cardiovascular risk factors in employed Swedish men and women: baseline results from the WOLF Study. J Epidemiol Community Health 1998;52: 540-7.
35. Mattiasson I, Lindgarde F. The effect of psychosocial stress and risk factors for ischaemic heart disease on the fibrinogen concentration. J Intern Med 1993;234:45-51.
36. Ishizaki M, Tsuritani I, Noborisaka Y, Yamada Y, Tabata M, Nakagawa H. Relationship between job stress and plasma fibrinolytic activity in male Japanese workers. Int Arch Occup Environ Health 1996;68:315-20.
37. Appels A, Mulder P. Fatigue and heart disease: the association between 'vital exhaustion' and past, present and future coronary heart disease. J Psychosom Res 1989;33:727-38.
38. Räikkönen K, Lassila R, Keltikangas-Järvinen L, Hautanen A. Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol 1996;16:363-7.
39. Kop WJ, Hamulyak K, Pernot C, Appels A. Relationship of blood coagulation and fibrinolysis to vital exhaustion. Psychosom Med 1998;60:352-8.
40. Siegrist J, Peter R, Junge A, Cremer P, Seidel D. Low status control, high effort at work and ischemic heart disease: prospective evidence from blue-collar men. Soc Sci Med 1990;31: 1127-34.
41. Bosma H, Peter R, Siegrist J, Marmot M. Two alternative job stress models and the risk of coronary heart disease. Am J Public Health 1998;88:68-74.
42. Siegrist J. Reciprocity in basic social exchange and health: can we reconcile person-based with population-based psychosomatic research? J Psychosom Res 1998;45:99-105.
43. Hockey GRJ, Payne RL, Risk JT. Intra-individual patterns of hormonal and affective adaptation to work demands: an n = 2 study of junior doctors. Biol Psychol 1996;42:393-411.
44. Jones F, Fletcher BC. Taking work home: a study of daily fluctuations in work Stressors, effects on moods and impacts on marital partners. J Occup Organ Psychol 1996;69:89-106.
45. Pollard TM, Ungpakorn G, Ainsworth Harrison G, Parkes KR. Epinephrine and cortisol responses to work: a test of the models of Frankenhaeuser and Karasek. Ann Behav Med 1996;18: 229-37.
46. van Eck M, Berkhof H, Nicolson N, Sulon J. The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. Psychosom Med 1996;58:447-58.
47. Kirschbaum C, Prussner JC, Stone AA, Federenko I, Gaab J, Lintz D, Schommer N, Hellhammer DH. Persistent high cortisol responses to repeated psychological stress in a subpopulation of healthy men. Psychosom Med 1995;57:468-74.
48. Holmäng A, Björntorp P. The effect of cortisol sensitivity in muscle. Acta Physiol Scand 1992;144:425-31.
49. Hautanen A, Adlercreutz H. Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med 1993;234:461-9.
50. Matschinger H, Siegrist J, Siegrist K, Dittmann K. Type A as a coping career: toward a conceptual and methodological redefinition. In: Schmidt TH, Dembroski TM, Blümchen G, editors. Biological and psychological factors in cardiovascular disease. Berlin: Springer; 1986. p. 104-26.
51. Rothenbacher D, Peter R, Bode G, Adler G, Brenner H. Dyspepsia in relation to Helicobacter pylori infection and psychosocial work stress in white collar employees. Am J Gastroenterol 1998; 93:1443-9.
52. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
53. Walker ID. Blood collection and sample preparation: preanalytical variation. In: Jespersen J, Bertina RM, Haverkate F, editors. Laboratory techniques in thrombosis - a manual. Second revised edition of the ECAT assay procedures. Dordrecht: Kluwer Academic Publishers; 1992: p. 21-8.
54. Meijer P, Pollet DE, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem 1994;40:110-5.
55. Krulder JWM, Meyer P, Kluft C. Plasminogen activator inhibitor-1 (PAI-1) antigen, PAI activity and tissue type plasminogen activator (tPa) antigen have, in bedridden volunteers, a diurnal rhythm with approximately the same phase and a peak late in the morning. Fibrinolysis 1992;6:83-4.
56. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996;86:726-8.
57. Brindley DN, McCann BS, Niaura R, Stoney CM, Suarez EC. Stress and lipoprotein metabolism: modulators and mechanisms. Metabolism 1993;42(9 suppl 1):3-15.
58. Halford WK, Cuddihy S, Mortimer RH. Psychological stress and blood glucose regulation in type I diabetic patients. Health Psychol 1990;9:516-28.
59. Alessi MC, Juhan-Vague I, Declerck PJ, Anfosso F, Gueunoun E, Collen D. Correlations between tPa and PAI-1 antigen and activity and tPa/PAI-1 complexes in plasma of control subjects and of patients with increased tPa or PAI-1 levels. Thromb Res 1990;60:509-16.
60. Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10(suppl 2):171-9.
61. McCann BS, Warnick GR, Knopp RH. Changes in plasma lipids and dietary intake accompanying shifts in perceived workload and stress. Psychosom Med 1990;52:97-108.
62. Rosengren A, Wilhelmsen L, Welin L, Tsipogianni A, Teger-Nilsson A, Wedel H. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. BMJ 1990;300: 634-8.
63. Brunner EJ, Marmot MG, Nanchahal K, Shipley MJ, Stansfeld SA, Juneja M, Alberti KGMM. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 1997;40:1341-9.
64. Johnson JV, Steward W, Hall EM, Hall EM, Fredlund P, Theorell T. Long-term psychosocial work environment and cardiovascular mortality among Swedish men. Am J Public Health 1996;86: 324-31.
65. Falger PRJ, Schouten EGW. Exhaustion, psychological stressors in the work environment, and acute myocardial infarction in adult men. J Psychosom Res 1992;36:777-86.
66. Appels A, Mulder P. Excess fatigue as a precursor of myocardial infarction. Eur Heart J 1988;9:758-64.
67. Räikkönen K, Keltikangas-Järvinen L, Adlercreutz H, Hautanen A. Psychosocial stress and the insulin resistance syndrome. Metabolism 1996;45:1533-8.
68. Henry J, Stephen PM. Stress, health and the social environment: a sociobiological approach to medicine. New York: Springfield; 1977.
69. Björntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 1991;230:195-201.
70. Keltikangas-Järvinen L, Räikkönen K, Hautanen A, Adlercreutz H. Vital exhaustion, anger expression and pituitary and adrenocortical hormones: implications for the insulin resistance syndrome. Thromb Vase Biol 1996;16:275-80.
71. Nilsson PM, Moller L, Soltad K. Adverse affects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med 1995;237:479-486.